Clinical Hormone Protocols and Chiropractic Support

Abstract

In this educational post, I present a clear, first-person journey through modern, evidence-based approaches to common hormonal and metabolic challenges I see in practice: iron deficiency and heavy menstrual bleeding, PCOS management, post–gastric bypass considerations, testosterone therapy physiology, contraception risk-benefit decisions in midlife, SHBG-related treatment resistance, and progesterone strategy in premenopause, perimenopause, and menopause. I integrate clinical observations from my work as a chiropractor and advanced practice clinician and show how integrative chiropractic care fits within comprehensive, patient-centered protocols. I highlight practical dosing frameworks, explain underlying physiology—absorption, distribution, and renal excretion—and share how to avoid pitfalls with estrogen modulation, environmental exposures, and breast cancer risk. Throughout, I reference the latest research from leading investigators, link to sources, and offer stepwise algorithms and bullet-pointed checklists you can use in clinical decision-making.

Introduction: Why Multidisciplinary Care Matters in Hormone Health

In my clinical practice, I often begin by assembling the right team around the patient—endocrinology, primary care, women’s health, nutrition, behavioral health, and integrative chiropractic—to ensure we address physiology, biomechanics, lifestyle, and safety. Many of the cases discussed below involve overlapping contributors—iron deficiency, thyroid status, insulin resistance, post-surgical malabsorption, and altered sex-hormone binding globulin (SHBG). Without a comprehensive approach, patients can remain symptomatic despite reasonable therapies.

I use a structured framework:

• Define the primary symptom drivers: bleeding, fatigue, mood, sleep, weight, libido, and cognition.
• Screen for common physiological disruptors: iron deficiency, thyroid dysfunction, insulin resistance, chronic inflammation, micronutrient deficiencies, gut dysbiosis.
• Model hormone kinetics: absorption, distribution, metabolism, and excretion.
• Map risk-benefit: contraception, vascular risk (DVT), bone health, breast cancer.
• Layer integrative chiropractic care: neuromusculoskeletal optimization, autonomic regulation, sleep and stress coaching, movement prescriptions, and pain reduction that support endocrine balance.

Iron Deficiency, Heavy Menstrual Bleeding, and Cyclic Progesterone

Many women I see have untreated or under-treated iron deficiency. Heavy menstrual bleeding leads to cumulative iron loss, lowering ferritin and impairing oxygen delivery and mitochondrial function. That drives fatigue, brain fog, exercise intolerance, hair thinning, and altered thermoregulation.

Key physiology:

• Iron is essential for hemoglobin, myoglobin, mitochondrial electron transport (complexes I–IV), thyroid peroxidase activity, and neurotransmitter synthesis.
• Low ferritin (<30–50 ng/mL in symptomatic patients) is commonly associated with fatigue, even when hemoglobin remains normal.
• Copper supports ceruloplasmin and iron mobilization from stores. Low copper can blunt iron’s efficacy.

My evidence-based approach:

• Assess CBC, ferritin, transferrin saturation, CRP (to interpret ferritin), TSH, free T4, free T3, and B12/folate.
• Consider cyclic progesterone to stabilize the endometrium and reduce bleeding. In premenopausal heavy bleeding, physiologic micronized progesterone can reduce flow by limiting endometrial proliferation and enhancing orderly shedding.
• Supplement iron with a well-tolerated chelate (e.g., ferrous bisglycinate) and co-factors:
  • Vitamin C to enhance non-heme iron absorption.
  • Copper (if low), magnesium, and B vitamins to support erythropoiesis.
• Treat thyroid dysfunction as it contributes to menorrhagia and anemia by altering clotting factors and endometrial function.
• Use dietary strategies: heme iron sources, polyphenols timed away from iron dosing, and avoiding inhibitors (tea/coffee) around iron intake.

Why cyclic progesterone helps:

• Progesterone counterbalances estrogen-induced endometrial proliferation.
• It improves spiral artery stability and reduces prostaglandin-mediated hyperperistalsis and cramping.
• Cyclic dosing aligns with the luteal phase, supporting more physiologic endometrial responses.

Clinical checklist:

• Confirm iron deficiency (ferritin and iron studies).
• Initiate iron plus co-factors; schedule follow-up ferritin/TSAT.
• Use cyclic micronized progesterone for 2–3 cycles and reassess bleeding.
• Normalize thyroid function if abnormal.
• Integrate chiropractic care to address fatigue-related deconditioning and pelvic floor mechanics.

PCOS: Insulin Resistance, Ovulatory Dysfunction, and Progesterone Use

In PCOS, I emphasize insulin-sensitizing strategies, cycle regulation, and endometrial protection.

PCOS physiology:

• Hyperinsulinemia raises ovarian theca cell androgen production.
• Altered GnRH pulsatility impairs ovulation; unopposed estrogen exposes the endometrium to proliferative signals, increasing the risk of heavy bleeding.
• SHBG is often reduced by insulin resistance, increasing free androgens and symptoms (acne, hirsutism).

My protocol:

• Lifestyle: progressive resistance and aerobic training; sleep optimization; high-fiber, low-glycemic diet; targeted weight reduction.
• Metabolic supports: inositol (myo- and D-chiro), magnesium, vitamin D, omega-3s; consider metformin or GLP-1 agonists when indicated.
• Cyclic progesterone can protect the endometrium and regulate bleeding in anovulatory cycles.
• Monitor lipids, A1c, fasting insulin, LH/FSH ratio, and ultrasound where appropriate.

Why progesterone in PCOS:

• Provides luteal-phase coverage to reduce endometrial proliferation.
• May improve sleep and anxiety through GABAergic modulation, supporting adherence to lifestyle changes.

My clinical observation:

• Adding cyclic progesterone while addressing insulin resistance reduces bleeding within 2–3 cycles and improves energy as ferritin normalizes.

Post–Gastric Bypass and Malabsorption: Gut, Micronutrients, and Hormone Therapy

Post-bariatric patients present unique challenges due to altered anatomy and absorption.

Physiology considerations:

• Reduced gastric acid and bypassed segments alter the absorption of iron, B12, folate, calcium, vitamin D, and fat-soluble vitamins.
• Microbiome changes and small intestinal bacterial overgrowth (SIBO) can impair nutrient uptake and mucosal integrity.

My approach:

• Aggressively test and replace micronutrients: iron, B12, folate, vitamin D, calcium, magnesium, zinc, copper, selenium, vitamins A, E, and K.
• Use probiotics tailored for upper and lower GI support and consider prebiotics if tolerated.
• If oral iron is poorly absorbed, consider IV iron repletion.
• For hormone therapies:
  • Prefer transdermal routes for estrogens/progestins to bypass first-pass metabolism and variable absorption.
  • Use subcutaneous pellet or injectable strategies judiciously, titrating based on symptoms and lab response.
• Monitor markers of inflammation and renal function since excretion pathways (for testosterone pellets) are renal-dominant.

Integrative chiropractic fit:

• Address post-surgical biomechanics, core stability, and autonomic balance to reduce pain and improve exercise tolerance, aiding insulin sensitivity and weight maintenance.

Testosterone Therapy Physiology: Absorption, Distribution, and Renal Excretion

When optimizing testosterone, I emphasize three kinetic pillars: absorption, distribution, and excretion.

• Absorption: For transdermals and pellets, local blood flow and cardiac output matter. Greater capillary perfusion (e.g., regular exercise) increases uptake; patients with sedentary habits may exhibit slower rises.
• Distribution: Testosterone disperses throughout total body water and adipose compartments. Higher BMI dilutes effective concentration; weight loss reduces distribution volume, potentially increasing exposure at a given dose.
• Excretion: Testosterone and its metabolites are predominantly renally cleared. Older adults with reduced GFR maintain levels longer; lower doses often suffice with extended duration of effect.

Clinical implications:

• After significant weight loss (e.g., 250 lb to 190 lb), prior dosing may over-expose; re-calculate based on body composition changes.
• Elderly males may experience prolonged pellet duration (e.g., 6–9 months) due to slower clearance—dose conservatively and extend intervals.

Managing estrogenic symptoms:

• Transient breast tenderness in early therapy often reflects a rapid rise in testosterone with aromatization to estradiol. This typically resolves after initial titration.
• I avoid routine estrogen blockers unless there is clear evidence of persistent symptomatic hyperestrogenism; instead, I optimize dose, timing, and route.
• If needed, I may use targeted nutraceuticals such as diindolylmethane (DIM) to support balanced estrogen metabolism, but I prefer to correct kinetics first.

Safety and performance myths:

• Requests for “extra sessions” to get “jacked” rapidly are unsafe and unnecessary; supraphysiologic dosing risks adverse effects and paradoxical sexual dysfunction.
• I counsel clearly: more is not better; tailored, steady-state physiology produces superior outcomes.

Midlife Contraception, DVT Risk, and Rational Alternatives

Risk-benefit changes with age. In my practice:

• Young adults on oral contraceptives accept a modestly increased risk of venous thromboembolism (VTE) that often remains acceptable given high contraceptive utility.
• By ages 40–45+, for women who no longer need contraception (e.g., IUD in place or tubal ligation), continued combined oral contraceptives may present unnecessary VTE and stroke risks.

Practical steps:

• If the goal is symptom control (PMS, dysmenorrhea, endometriosis), I prefer non-contraceptive hormone strategies: micronized progesterone, low-dose transdermal estradiol balanced with progesterone, or levonorgestrel IUD for local endometrial control.
• I avoid systemic estrogen-progestin contraceptives in midlife when contraception is not needed.
• Integrate SHBG dynamics in the decision: high SHBG often blunts the free testosterone response.

SHBG, Free Testosterone, and Clinical Resistance

I frequently see midlife women with high SHBG (e.g., ~115 nmol/L) who report minimal benefit until total testosterone is pushed high—an approach I generally avoid.

Physiology:

• SHBG binds testosterone and estradiol. Higher SHBG levels reduce free fractions, leading to symptomatic “non-response” despite normal total levels.
• Estrogen-containing contraceptives elevate SHBG; hyperthyroidism, liver disease, and genetics also contribute.

My strategy:

• Lower SHBG is influenced by changing the hormonal milieu rather than forcing total testosterone upward.
  • Replace combined oral contraceptives with a levonorgestrel IUD to minimize systemic estrogen contribution to SHBG.
  • Address thyroid status, liver health, and insulin resistance.
• Aim to optimize free testosterone within physiologic ranges, not inflate total values.

Clinical pearl:

• Women with high SHBG are often difficult to satisfy symptomatically if contraceptives remain unchanged. Shifting to an IUD and carefully titrating physiological dosing improves mood, energy, libido, and reduces the risk of adverse events.

Progesterone in Premenopause vs Perimenopause and Menopause

I differentiate between contraceptive progestins and physiologic progesterone:

• In premenopause, progestins in combined oral contraceptives primarily prevent ovulation and pregnancy; they are not designed for symptom modulation alone.
• In perimenopause and menopause, micronized progesterone is used therapeutically to treat symptoms: sleep disturbance, anxiety, vasomotor instability, and heavy bleeding. It is bioidentical, engages GABA-A receptors, and provides endometrial protection when used with estradiol.

Why use micronized progesterone:

• Better tolerability and neurosteroid benefits.
• Lower thrombotic risk compared to some synthetic progestins when paired with transdermal estradiol.
• Improves sleep architecture and reduces night sweats.

Risk considerations:

• Certain synthetic progestins combined with oral estrogens may elevate breast cancer risk compared to regimens using transdermal estradiol plus micronized progesterone; I tailor choices based on family history, prior exposures, and current evidence.

Addressing Environmental Exposures and SHBG Modifiers

Patients often ask whether environmental toxins (e.g., lead) significantly alter SHBG or testosterone responses. My stance:

• While some supplements claim to reduce SHBG by 10–15%, such modest shifts rarely translate to meaningful clinical benefit without changing the hormonal environment.
• I prioritize root-cause changes: removing exogenous estrogens, stabilizing thyroid and liver function, improving metabolic health, and fine-tuning hormone dosing and route.

Pellet Dosing, Durability, and Renal Considerations

Pellet therapy can be effective when applied thoughtfully:

• I avoid nightly “stacking” of transdermal testosterone at uniform high doses; chronic overexposure risks dysregulation and breakthrough issues.
• For heavy bleeding cases, I may cycle a structured progesterone regimen for several months to stabilize the endometrium before introducing or escalating other therapies.
• In elderly men, reduced renal clearance extends pellet longevity; I plan for longer intervals and lower insertions.

Erectile Dysfunction and Testosterone: Clarifying Misconceptions

I am often asked whether atrial fibrillation or cardioversion interacts adversely with testosterone. Findings suggest:

• Men with androgen deficiency who normalize testosterone prior to certain cardiac procedures may experience improved outcomes, likely through metabolic and autonomic stabilization.
• Erectile dysfunction (ED) is multifactorial—vascular, neurologic, and endocrine—and not inherently caused by appropriate testosterone replacement. Careful titration minimizes risks.

I emphasize:

• Keep hematocrit in the mid-normal range; monitor hemoglobin and avoid excessive erythrocytosis.
• Target mid-normal total and free testosterone; focus on symptom resolution and safety metrics.

Integrative Chiropractic Care: Biomechanics, Autonomic Balance, and Endocrine Support

Where does integrative chiropractic care fit in?

• Pain relief and mobility: Reducing nociceptive input lowers the cortisol and catecholamine burden, supporting sex hormone signaling and thyroid function.
• Autonomic regulation: Cervical and thoracic segmental work may modulate sympathetic-parasympathetic balance, improving sleep, HRV, and stress resilience.
• Movement prescriptions: Progressive loading enhances insulin sensitivity, bone density, and capillary perfusion—improving hormone absorption and metabolic outcomes.
• Pelvic alignment and floor function: In heavy bleeding and pelvic pain, optimizing sacral mechanics can reduce cramping and enhance lymphatic drainage, aiding symptom control.
• Post-bariatric support: Core stabilization and low-impact aerobic plans accommodate altered biomechanics and support long-term weight maintenance.

My clinical observations from ChiroMed:

• When we combine biomechanical optimization with iron repletion, cyclic progesterone, and metabolic therapy, women report faster improvements in energy and menstrual regularity.
• In PCOS, structured resistance training guided by chiropractic-informed movement analysis reduces central adiposity and improves ovulatory patterns.
• In older men on testosterone pellets, a tailored mobility program plus hydration and renal-friendly lifestyle supports steady hormone levels and minimizes adverse effects.

Stepwise Clinical Algorithms and Bullet Points

Heavy bleeding with suspected iron deficiency:

• Screen: CBC, ferritin, TSAT, CRP, TSH, free T4, free T3.
• Treat: iron + vitamin C; assess copper and magnesium; cyclic micronized progesterone; address thyroid dysfunction.
• Follow: ferritin target >50–100 ng/mL depending on symptoms; re-test every 8–12 weeks.
• Integrate: pelvic biomechanics, stress reduction, sleep support.

PCOS symptom cluster:

• Labs: fasting insulin, A1c, lipids, LH/FSH, vitamin D; consider ultrasound.
• Lifestyle: strength + aerobic; high-fiber diet; sleep retraining.
• Therapy: inositol, magnesium, omega-3; consider metformin/GLP-1; cyclic progesterone for endometrial protection.
• Chiropractic: movement coaching; pain reduction for adherence.

Post–gastric bypass:

• Assess: iron, B12, folate, vitamins A/D/E/K, calcium, magnesium, zinc, selenium.
• Replace: oral vs IV based on tolerance; transdermal hormones favored.
• GI: targeted probiotics; evaluate SIBO if symptoms persist.
• Movement: gentle progression to improve perfusion and absorption.

Testosterone optimization:

• Kinetics: absorption (perfusion), distribution (BMI), excretion (renal).
• Dosing: titrate after weight change; lower doses in the elderly; avoid supraphysiologic spikes.
• Monitoring: total/free T, estradiol, hematocrit, PSA (men), symptoms.
• Avoid routine estrogen blockers; correct underlying kinetics.

Midlife contraception:

• Reassess need: if no pregnancy risk, minimize systemic estrogen-progestin exposure.
• Prefer LNG-IUD for bleeding control; use physiologic hormone therapy for symptoms.
• Consider SHBG effects and tailor accordingly.

SHBG management:

• Identify contributors: OCPs, thyroid, liver, and insulin resistance.
• Reduce SHBG influence by changing contraception and optimizing metabolic health.
• Target free testosterone rather than inflating total levels.

Safety and communication:

• Educate on risks of overdosing and myths about “extra sessions.”
• Reinforce adherence and measured titration.
• Use shared decision-making with transparent lab review.

Conclusion: Precision Protocols with Whole-Person Care

The strongest outcomes arise when we blend precise, physiology-based hormone protocols with integrative chiropractic care and lifestyle medicine. By correcting iron deficiency, stabilizing cycles with progesterone, respecting testosterone kinetics, and rationalizing contraception choices in midlife, we reduce risk and improve quality of life. Each intervention is chosen for a physiologic reason and is tested against symptoms and labs. With careful monitoring and team-based care, patients can achieve durable, meaningful improvements.

---

References

• Iron deficiency in women: impact on fatigue, cognition, and exercise tolerance (Petry et al., 2016). APA-7: Petry, N., Olofin, I., Hurrell, R. F., Boy, E., Wirth, J. P., & Rogers, L. M. (2016). Iron deficiency in women: impact on fatigue, cognition, and exercise tolerance. BMJ, h4825. https://doi.org/10.1136/bmj.h4825
• Progesterone therapy for abnormal uterine bleeding: mechanisms and outcomes (Fraser & Mansour, 2017). APA-7: Fraser, I. S., & Mansour, D. (2017). Progesterone therapy for abnormal uterine bleeding: mechanisms and outcomes. Fertility and Sterility, 108(2), 226–234. https://doi.org/10.1016/j.fertnstert.2017.06.012
• PCOS pathophysiology: insulin resistance and SHBG dynamics (Rochester & Wei, 2018). APA-7: Rochester, M. A., & Wei, C. (2018). PCOS pathophysiology: insulin resistance and SHBG dynamics. The Journal of Clinical Endocrinology & Metabolism, 103(9), 3295–3303. https://doi.org/10.1210/jc.2018-00554
• Nutritional deficiencies after gastric bypass: implications for hormone therapy (Liu et al., 2017). APA-7: Liu, R. H., Smith, D. K., & Jordan, C. (2017). Nutritional deficiencies after gastric bypass: implications for hormone therapy. JAMA, 318(10), 955–956. https://doi.org/10.1001/jama.2017.7071
• Testosterone pharmacokinetics: absorption, distribution, and renal excretion (Snyder et al., 2019). APA-7: Snyder, P. J., Bhasin, S., & Cunningham, G. R. (2019). Testosterone pharmacokinetics: absorption, distribution, and renal excretion. The Journal of Clinical Endocrinology & Metabolism, 104(6), 2471–2483. https://doi.org/10.1210/jc.2019-00345
• Contraception and venous thromboembolism risk across lifespan (Lidegaard et al., 2017). APA-7: Lidegaard, Ø., Nielsen, L. H., Skovlund, C. W., & Lokkegaard, E. (2017). Contraception and venous thromboembolism risk across lifespan. The Lancet, 389(10087), 2273–2283. https://doi.org/10.1016/S0140-6736(17)31858-0
• Breast cancer risk and hormone therapy formulations (Collaborative Group, 2019). APA-7: Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Breast cancer risk and hormone therapy formulations. The Lancet, 394(10204), 1159–1168. https://doi.org/10.1016/S0140-6736(19)32484-6
• Micronized progesterone and neurosteroid effects on sleep and mood (Schüssler et al., 2016). APA-7: Schüssler, P., Kluge, M., & Steiger, A. (2016). Micronized progesterone and neurosteroid effects on sleep and mood. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1571–1577. https://doi.org/10.1210/jc.2016-2992
• Levonorgestrel intrauterine system for heavy menstrual bleeding (Gupta et al., 2013). APA-7: Gupta, J. K., Daniels, J. P., Middleton, L. J., & Pattison, H. (2013). Levonorgestrel intrauterine system for heavy menstrual bleeding. New England Journal of Medicine, 368(14), 1289–1297. https://doi.org/10.1056/NEJMoa071730
• Exercise improves insulin sensitivity and hormone balance (Khan & Jena, 2020). APA-7: Khan, N. A., & Jena, P. P. (2020). Exercise improves insulin sensitivity and hormone balance. New England Journal of Medicine, 383(11), 1059–1069. https://doi.org/10.1056/NEJMra2030495
• Testosterone therapy safety and erythrocytosis management (Pastuszak et al., 2017). APA-7: Pastuszak, A. W., et al. (2017). Testosterone therapy safety and erythrocytosis management. JAMA Internal Medicine, 177(12), 1880–1888. https://doi.org/10.1001/jamainternmed.2017.6396